American Cancer Society Matt Cooperberg Jonathan Evan Shoag 🇮🇱🇺🇸 Andrew Vickers Amer. Urol. Assn. ASCO ASTRO PCF Science Todd 〽️ Morgan, MD Edward Schaeffer, MD, PhD NRG Oncology Veracyte, Inc. Elai Davicioni Joe Biden Amar Kishan National Cancer Institute 14/x While men who are 75 are of course at higher risk of dying from something other than PCa, using social security data, ~1 in 4 men that are 75yo will live until 90yo or older. Given such a high % of older men present with regional or distant mets, you are putting a lot of

Uromigos unsung prostate cancer hero #ASC025 @dolmos77 - David Olmos - 50% 8 year OS for M1 1st line disease - but subgroups (PSMA+ve and BRCA) still have less good outcomes. Opportunities for further therapy her e with PARPi and LuPSMA (+ve PSMA addition and amplitude studies)

A Comprehensive Systematic Review and Meta-analysis of the Role of Prostate-specific Membrane Antigen Positron Emission Tomography for Prostate Cancer Diagnosis and Primary Staging before Definitive Treatment sciencedirect.com/science/articl… This systematic review and meta-analysis

🧬 BRCA mutations = worse prognosis in all mHSPC, regardless of disease volume or treatment. Risk stratification should include genomics. Congratulations David and all team. 👏👏👏 David Olmos Elena Castro Daniel Castellano Annals of Oncology Tom Powles Advanced Prostate Cancer Consensus Conference OncoAlert

I learned this week that SABR-COMET patient #1 recently passed away, more than 12 years after enrollment, with no recurrence since his original SABR. We initially treated him for a left adrenal met. It’s an interesting story… ⬇️⬇️⬇️

Want a Sunday morning reading with a sip of coffee? Here is one (in press) for #PCSM enthusiasts! sciencedirect.com/science/articl… Always grateful for the support and motivation from Daniel E Spratt even during tough times and Yilun Sun for teaching me new things every time!!

STAMPEDE: ADT leads to high fracture rates in prostate cancer, esp. with mets. Zoledronic acid lowers fracture risk in metastatic, not non-metastatic. Should we add ZA or Deno in bone protecting dose? #prostatecancer #Oncology Annals of Oncology Advanced Prostate Cancer Consensus Conference OncoAlert

Seminars in Radiation Oncology Elsevier is pleased to share "Debate 3: Metastasis Directed Therapy in Oligometastatic Prostate Cancer" by Dr. Maneesh Singh, Dr. Vedang Murthy Vedang Murthy, Dr. Piet Ost Piet Ost sciencedirect.com/science/articl…

SCU 2025 Sociedad Colombiana de Urología Julian Chavarriaga with a Tour de Force presentation highlighting biomarkers in localized, locally advanced, and mCSPC prostate cancer 👇A tailored approached to mCSPC in the future UroToday.com

Dave Penson Sociedad Colombiana de Urología Julian Chavarriaga UroToday.com Although DE-ESCALATE is assessing intermittent ADT in patients with PSA <0.2 after ADT + ARPI

Yes Maha Hussain’s SWOG 9346 (NEJM 2013) tested IAB vs CAB with inconclusive results for OS (HR 1.1, 95% CI 0.99 - 1.23)

First study of ureteral toxicity of mostly (>95%) 5Fx SBRT suggests current constraints (e.g. Timmerman D0.035cc <45 Gy) may be too strict. Only 1/16 pts exceeded D0.1cc >108 Gy EQD2 (~45 Gy/5Fx) and developed late toxicity Great work! #radonc IJROBP - The Red Journal redjournal.org/article/S0360-…

CHAARTED Ten-year survival rates: Time to re-think de-escalation! Achieving a PSA nadir below 0.2 ng/mL within 6 months is a strong predictor of overall survival, supporting its role in response-adapted de-escalation strategies. Annals of Oncology ESMO - Eur. Oncology ECOG-ACRIN Cancer Research Group Elizabeth Plimack MD

Repetition is the name of the brain game. Repeat what you want to become. This is neuroplasticity.

How much can a GG2 #ProstateCancer grow in 2 months? R: baseline, L: 2 months later. T2-weighted. More slices in next tweet.

Another proof that metastasis directed therapy improves outcomes, this time in castration resistant #prostatecancer Congrats to the PCS IX team! author link at The Lancet Oncology: authors.elsevier.com/a/1liJQ5EIIgTS…

A.E

🔥 PCS-9: SBRT + ENZA Doubles Disease Control in Oligometastatic CRPC OncoAlert Fabio Cury 🎯 Objective • Evaluate whether adding SBRT to ADT + enzalutamide ⬆️ outcomes in oligometastatic CRPC (≤5 mets) 🏥 Methods • Ph 2, randomized, 13 Canadian centers. • 100 men with

💥 SBRT in omCRPC: From delay ➝ domination? PCS-9 🔬: Randomized phase 2 (n=100; ≤5 mets, ECOG 0–1, conventional imaging; 13 Canadian centres; Lancet Oncology 2025) 🦾 Arms: • A) ADT + Enzalutamide 💊 • B) ADT + Enzalutamide 💊 + SBRT to all oligomet sites 🎯 📊 Key

Excited to share our recent LancetOncology publication on sequential SBRT for oligometastatic clear cell RCC. Our outcomes show excellent outcomes in 121 patients with 1-5 metastases. MD Anderson Cancer Center Myriad Genetics authors.elsevier.com/a/1ljMf5EIIgTS…